Handan He has left her role as global head of computational, biopharmaceutics and translational PK/PD at Novartis’ (NOVN: VX) pharma unit to join Ascletis (1672: HK) as chief scientific officer.
Ascletis is a Chinese biotech company addressing unmet medical needs in therapeutic areas including anti-viral, cancer and fatty liver diseases with two products currently on the market.
Dr He’s experience with Novartis saw her manage scientific teams across global sites in the USA and Switzerland. She worked for the Swiss pharma giant for 22 years.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze